Renova takes over rights to heart failure candidate stresscopin from Janssen

US-based Renova Therapeutics has signed an agreement to receive the investigational new drug (IND) file for stresscopin from Janssen Pharmaceuticals.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news